Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study

Journal:

Journal of Hepatology

Published:

2025-05-16

DOI:

10.1016/j.jhep.2025.05.003

Affiliations:

26

Authors:

20

Go to article

Institutions	Authors	Share
Georgetown Lombardi Comprehensive Cancer Center, United States of America (USA)	1.000000	0.05
Affiliated Jinling Hospital, NJU, China	1.000000	0.05
National Cancer Center Hospital, Japan	1.000000	0.05
Seoul National University Bundang Hospital (SNUBH), South Korea	1.000000	0.05
Chiang Mai University (CMU), Thailand	1.000000	0.05
Seoul St. Mary's Hospital, South Korea	1.000000	0.05
Wakayama Medical University, Japan	1.000000	0.05
Sarah Cannon Research Institute (SCRI), United States of America (USA)	1.000000	0.05
AP-HP Beaujon Hospital, France	1.000000	0.05
King Chulalongkorn Memorial Hospital, Thailand	1.000000	0.05
Medical University of Gdańsk (MUG), Poland	1.000000	0.05
IRCCS Istituto Nazionale Tumori IRCCS-Fondazione G. Pascale, Italy	1.000000	0.05
Instituto de Diagnóstico e Investigaciones Metabólicas, Argentina	1.000000	0.05
AstraZeneca Poland, Poland	1.000000	0.05
AstraZeneca United States, United States of America (USA)	1.000000	0.05
AstraZeneca, United Kingdom (UK)	1.000000	0.05
Seoul National University Hospital (SNUH), South Korea	0.500000	0.03
Seoul National University (SNU), South Korea	0.500000	0.03
Cholangiocarcinoma Foundation, United States of America (USA)	0.500000	0.03
The University of Manchester (UoM), United Kingdom (UK)	0.500000	0.03
Kaohsiung Medical University Gangshan Hospital, Taiwan	0.333333	0.02
National Health Research Institutes (NHRI), Taiwan	0.333333	0.02
National Cheng Kung University Hospital, Taiwan	0.333333	0.02
Toronto General Hospital (TGH), U of T, Canada	0.333333	0.02
Princess Margaret Cancer Centre, U of T, Canada	0.333333	0.02
Hannover Medical School (MHH), Germany	0.333333	0.02

Interested in Oncology and Carcinogenesis?